concizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
monoclonal antibodies (humanized origin); cardiovascular 5760 1312299-39-0

Description:

MoleculeDescription

Molfile

Synonyms:

  • concizumab
  • alhemo
  • NNC172-2021
  • NN7415
  • NNC 0172-0000-2021
Concizumab is a monoclonal antibody used for the treatment of hemophilia B. It is an anti-tissue factor pathway inhibitor.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Sept. 25, 2023 PMDA Novo Nordisk Pharma

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B02BX10 BLOOD AND BLOOD FORMING ORGANS
ANTIHEMORRHAGICS
VITAMIN K AND OTHER HEMOSTATICS
Other systemic hemostatics
FDA EPC N0000194160 Tissue Factor Pathway Inhibitor Antagonist
FDA MoA N0000194161 Tissue Factor Pathway Inhibitor Antagonists

Related Drugs by ATC class:

B02BX Other systemic hemostatics 10 drugs
avatrombopagcarbazochromeeltrombopagemicizumabetamsylatefitusiranfostamatiniblusutrombopagmarstacimab-hncqromiplostim

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Prophylactic treatment of hemophilia A and B indication 90935002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Tissue factor pathway inhibitor Secreted BINDING AGENT Kd 10.60 SCIENTIFIC LITERATURE DRUG LABEL

External reference:

IDSource
CHEMBL4297730 ChEMBL_ID
C574488 MESH_SUPPLEMENTAL_RECORD_UI
11182 IUPHAR_LIGAND_ID
DB12820 DRUGBANK_ID
4043679 VANDF
C3494079 UMLSCUI
CHEBI:757182 CHEBI
9636 INN_ID
41976 MMSL
d10108 MMSL
68603V9EAF UNII
2708333 RXNORM
1674471000168103 SNOMEDCT_US
D11847 KEGG_DRUG

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Alhemo HUMAN PRESCRIPTION DRUG LABEL 1 0169-2080 INJECTION, SOLUTION 100 mg SUBCUTANEOUS BLA 28 sections
Alhemo HUMAN PRESCRIPTION DRUG LABEL 1 0169-2081 INJECTION, SOLUTION 100 mg SUBCUTANEOUS BLA 28 sections
Alhemo HUMAN PRESCRIPTION DRUG LABEL 1 0169-2084 INJECTION, SOLUTION 40 mg SUBCUTANEOUS BLA 28 sections